-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Esperion Therapeutics, Raises Price Target to $5

Benzinga·03/03/2026 18:32:54
Listen to the news
Needham analyst Serge Belanger maintains Esperion Therapeutics (NASDAQ:ESPR) with a Buy and raises the price target from $4 to $5.